XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

Leukemia
18:13

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Pre-Pandemic CML Treatment: What Is CGA? How Do Ponatinib, Nilotinib & Dasatinib Affect Endothelial Function? What Are the COVID-19-Related Challenges in CML?

FEATURING Pia Raanani
  • 15 views
  • January 19, 2021
19:37

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Challenges in Treatment of Leukemias and Bone Marrow Failure in Developing Countries: Patients and Methods, Diagnosis. Treatment Plan, Supportive Care

FEATURING Kamran Rashid
  • 15 views
  • January 18, 2021
23:29

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

AML Treatment in Developing Countries: LIMC vs. HIC Differences - Studies, Median Age/OS, HSCT Submission, Early-Mortality Rates, Specialized Centers, Delay in Diagnosis

FEATURING Eduardo Rego
  • 13 views
  • January 18, 2021
15:57

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Cytogenetic Characterization in AML: How Do Gene Mutations Impact Overall Treatment Outcomes?

FEATURING Mehmet Yilmaz
  • 132 views
  • January 18, 2021
35:51

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Targeted Therapy for Older Patients With AML: Is Addition of GO to Induction Chemo Beneficial? Does Chemo+/-Midostaurin Improve OS in Newly Diagnosed Disease? What About Ena & Ivo for R/R Disease?

FEATURING Charles A. Schiffer
  • 38 views
  • January 18, 2021
18:11

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

State of the Art in Adults With ALL: Salvage & 1L Ino and Blina + Chemo, Ponatinib-Blina in Ph+ Disease, Bcl2-Bclxl Inhibitors, CAR-T in Early Salvage and 1L

FEATURING Elias Jabbour
  • 23 views
  • January 18, 2021
14:29

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Better, Safer & Cheaper? Is There a Difference Between 2L Options? Is 3L Ponatinib Effective? Are Dose Reductions Effective and Safe? Is TFR Feasible?

FEATURING Elias Jabbour
  • 33 views
  • January 18, 2021
17:01

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Pediatric ALL Updates: What Is the COG Risk Stratification Approach? How Important Are TKIs? When Should Allo-HSCT Be Considered?

FEATURING Sema Anak
  • 11 views
  • January 15, 2021
16:00

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

ALL Highlights: Should We De-Escalate Chemo? Do TKIs (Dasatinib, Nilotinib) Improve OS? How Successful Is Chemo-Free Therapy For Ph+ Disease? Are Blina or Ino Effective IO Agents?

FEATURING Dieter Hoelzer
  • 13 views
  • January 15, 2021
23:41

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Ph+ and Ph-Like Adult Frontline ALL: What Is the Optimal Strategy in the TKI Era? Should MRD Be the Primary Goal? Can We Achieve CMR With Dasatinib-Blinatumomab?

FEATURING Robin Foa
  • 21 views
  • January 15, 2021
19:05

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

CAR-T in Pediatric ALL: Tisagenlecleucel in B-Cell Disease, CAR-T vs. Blina vs. Ino Ozogamicine, R/R CD19+ Neoplasm Relapsing After HSCT, Role of MRD

FEATURING Francesco Saglio
  • 16 views
  • January 15, 2021
30:27

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

CML Highlights: Has Molecular Monitoring Replaced Cytogenetic Monitoring? Is Imatinib Effective Initial Treatment in Chronic Phase? Are High-Risk ACA Associated With Reduced Survival?

FEATURING Rudiger Hehlmann
  • 17 views
  • January 12, 2021
28:52

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Molecular Monitoring and CML: What Is the Influence on Therapy and How Does It Help? What Are the Recommendations for TFR?

FEATURING Naeem Chaudhri
  • 13 views
  • January 12, 2021
31:57

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Recommendations for Treatment Discontinuation in CML: Is TFR Feasible? How Often to Monitor? What to Do After Early/Late Relapse?

FEATURING Carmen Fava
  • 13 views
  • January 12, 2021
11:53

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

CML Updates: Prognostic Factors, Conventional Drugs, 1L Therapy, Treatment Access/Monitoring, Resistance and 2L Therapy, Current Challenges in Developing Countries

FEATURING Waseem Sattar
  • 15 views
  • January 12, 2021
12:50

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

19 y/o Male With Jaundice and a Duodenal Ampulla Tumor: Does Standard Idarubicin + Cytarabine Regimen Help? Can AlloHSCT Prolong OS?

FEATURING Mustafa Merter
  • 11 views
  • January 12, 2021
15:31

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

AML Updates: Can CC-486 Improve OS in 1st Remission in Older Patients? Are Chemo+/-Midostaurin & Aza+/-Ven Successful Combos in Newly Diagnosed Disease?

FEATURING Guillermo Garcia-Manero
  • 123 views
  • January 11, 2021
20:42

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3-Mutated R/R Disease? CPX-351 vs. CYT+DNR - What to Choose in Newly Diagnosed Disease? Are Ivo/Ena + Aza Beneficial for Chemo-Ineligible Patients?

FEATURING Giovanni Martinelli
  • 57 views
  • January 11, 2021